Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy

References

• WijdicksEFHepatic encephalopathyN Engl J Med2016375171660167027783916
   PubMed Web of Science ®Google Scholar
• MullenKDReview of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathyAliment Pharmacol Ther200725Suppl 1111617295847
   PubMed Web of Science ®Google Scholar
• MorganMChapter 8: Hepatic encephalopathy in patients with cirrhosisDooleyJSLokABurroughsAHeathcoteJSherlock’s Diseases of the Liver and Biliary System12th edHoboken, NJ, USABlackwell Publishing2011121151
   Google Scholar
• BajajJSWadeJBSanyalAJSpectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathyHepatology2009502014202119787808
   PubMed Web of Science ®Google Scholar
• GilberstadtSJGilberstadtHZieveLBuegelBCollierROJrMcClainCJPsychomotor performance defects in cirrhotic patients without overt encephalopathyArch Intern Med198014045195217362383
   PubMedGoogle Scholar
• GitlinNLewisDCHinkleyLThe diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosisJ Hepatol19863175823745889
   PubMed Web of Science ®Google Scholar
• DasADhimanRKSaraswatVAVermaMNaikSRPrevalence and natural history of subclinical hepatic encephalopathy in cirrhosisJ Gastroenterol Hepatol200116553153511350549
   PubMed Web of Science ®Google Scholar
• D’AmicoGGarcia-TsaoGPagliaroLNatural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studiesJ Hepatol200644121723116298014
   PubMed Web of Science ®Google Scholar
• AlvarezMACireraISolaRBargalloAMorillasRMPlanasRLong-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patientsJ Clin Gastroenterol2011451090691121814145
   PubMed Web of Science ®Google Scholar
• BustamanteJRimolaAVenturaPJPrognostic significance of hepatic encephalopathy in patients with cirrhosisJ Hepatol199930589089510365817
   PubMed Web of Science ®Google Scholar
• PoordadFFReview article: the burden of hepatic encephalopathyAliment Pharmacol Ther200725Suppl 139
   PubMed Web of Science ®Google Scholar
• BassNMMullenKDSanyalARifaximin treatment in hepatic encephalopathyN Engl J Med2010362121071108120335583
   PubMed Web of Science ®Google Scholar
• RoggeriDPRoggeriARossiEOvert hepatic encephalopathy in Italy: clinical outcomes and health care costsHepat Med20157374226203290
   PubMedGoogle Scholar
• BajajJSWadeJBGibsonDPThe multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregiversAm J Gastroenterol201110691646165321556040
   PubMed Web of Science ®Google Scholar
• YounossiZMBoparaiNMcCormickMPriceLLGuyattGAssessment of utilities and health-related quality of life in patients with chronic liver diseaseAm J Gastroenterol200196257958311232711
   PubMed Web of Science ®Google Scholar
• ArguedasMRDeLawrenceTGMcGuireBMInfluence of hepatic encephalopathy on health-related quality of life in patients with cir-rhosisDig Dis Sci20034881622162612924658
   PubMed Web of Science ®Google Scholar
• GroenewegMQueroJCDe BruijnISubclinical hepatic encephalopathy impairs daily functioningHepatology199828145499657095
   PubMed Web of Science ®Google Scholar
• StepanovaMMishraAVenkatesanCYounossiZMIn-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009Clin Gastroenterol Hepatol20121091034.e11041.e122642955
   PubMed Web of Science ®Google Scholar
• American Gastroenterological AssociationThe Burden of Gastrointestinal DiseasesBethesda, MDAmerican Gastroenterological Association20014142
   Google Scholar
• OrrJGCurrieCJBerniEThe impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-αLiver Int20163691295130326950766
   PubMed Web of Science ®Google Scholar
• Associazione Italiana Per Lo Studio Del Fegato“Encefalopatia Epatica” dell’Associazione Italiana per lo Studio del Fegato. [Italian Association for the Study of the Liver. Hepatic Encephalopathy] Available from: http://www.webaisf.org/media/8045/encefalopatia_epatica.pdfAccessed June 30, 2017 Italian
   Google Scholar
• MullenDESanyalAJBassNMRifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathyClin Gastroenterol Hepatol20141281390.e21397.e224365449
   PubMed Web of Science ®Google Scholar
• Determina 14 settembre 2016 Riclassificazione del medicinale per uso umano «Tixteller», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 1211/2016). (16A07024) (GU Serie Generale n.230 del 01-10-2016). [Determination 14 September 2016. Reclassification of the medicinal product for use in human “Tixteller” within the meaning of Article 8, paragraph 10 of Law 24 December 1993, n. 537. (Determination No. 1211/2016). (16A07024) (General Series No.230 of 01-10-2016)] Available from: http://www.gazzettaufficiale.it/eli/id/2016/10/01/16A07024/sg;jsessionid=ss8SvRMtGRI4TzilOUkjAA__.ntc-as5-guri2aAccessed June 30, 2017 Italian
   Google Scholar
• KabeshovaALaunoisRCost-effectiveness analysis of rifaximin-α administration for the reduction of the overt hepatic encephalopathy episodes in recurrence in FranceValue Health2016197A513
   Web of Science ®Google Scholar
• PooleCDBerniEConwayPRadwanACurrieCJEvaluation of the cost effectiveness of rifaximin-α 550 mg in the reduction of recurrence of overt hepatic encephalopathy in SwedenValue Health2015187A626
   Web of Science ®Google Scholar
• BerniEPooleCDConwayPRadwanACurrieCJCost effectiveness of rifaximin-α 550 mg in the reduction of recurrence of overt hepatic encephalopathy in United KingdomValue Health2015187A626
   Web of Science ®Google Scholar
• BerniEConnollyMConwayPRadwanACurrieCJEvaluation of the cost effectiveness of rifaximin-α in the reduction of recurrence of overt hepatic encephalopathy in BelgiumValue Health2015187A628
   Web of Science ®Google Scholar